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1,2 Despite the relatively high incidence of AF in HCM and the morbidity associated with this arrhythmia, only a small number of studies have systematically addressed the clinical implications of AF in HCM, with many being published more than a decade ago. 2, 3 More recent investigations were based on multicenter study designs and were confined mainly to comparisons of patients with HCM with or without AF. [4] [5] [6] In this issue of Circulation, Rowin et al 7 from Tufts Medical Center report their findings on the clinical course and management of AF in an HCM cohort of >300 consecutive patients with clinically overt AF who were part of an HCM population of almost 1600 patients evaluated at their referral center over a period of 10 years. The mean period of follow-up was ≈5 years. Of the patients with AF, 74% had symptomatic paroxysmal AF and 26% had permanent AF. A series of important observations have emerged from this large cohort of patients with access to contemporary management of HCM.
A novel and important observation, which differs considerably from most of the previous HCM literature, is the generally favorable clinical course and outcome in the great majority of the study patients with AF. For example, ≈90% of the patients with AF were alive at the most recent evaluation, and the great majority were in New York Heart Association class I or II. Only 4% of patients with AF died of HCMrelated causes, for an annual mortality rate of 0.7%. In particular, deaths resulting from thromboembolic events, the modality of death most directly related to AF, [1] [2] [3] occurred in only 2 patients (annual mortality, 0.1%). Furthermore, the incidence of sudden death events, total HCM-related death, and all-cause mortality at 5 years was similar in patients with AF and an age-and sex-matched group of patients with HCM without AF. The incidence of severe heart failure (class III/IV symptoms) at 5 years was also similar in these 2 groups (≈20%) and in patients with outflow obstruction with or without AF (30%).
These observations cast a new and more favorable light on the impact of AF on the clinical course of HCM. But how can we explain these results? The important advances in the treatment of patients with HCM over the last 2 decades probably justify these findings. Sudden death, one of the most devastating manifestations of HCM, can be effectively prevented by the implantable cardioverter-defibrillator. 8, 9 LV outflow obstruction and heart failure symptoms can be relieved by surgical septal myectomy with an operative mortality ≤1%.
9,10 Thromboembolic events can be effectively prevented by the timely initiation of anticoagulation, 1 a therapy facilitated by the introduction of new direct oral anticoagulants.
The study by Rowin et al 7 is also characterized by a detailed analysis of the clinical course and management of various AF subgroups. About 25% of patients with documented AF experienced only a single symptomatic episode over a mean follow-up of 5 years, and left atrial dimension did not differ significantly between patients with a single AF episode and those with multiple AF episodes. These findings indicate that the timing of AF recurrences is difficult to predict in the individual patient with HCM, and a single AF episode may not justify the initiation of antiarrhythmic therapy to prevent recurrences, a treatment potentially associated with important side effects. Furthermore, subgroup analysis showed that almost 70% of the study patients who were in permanent AF at the initial evaluation or progressed from paroxysmal to permanent AF during follow-up were in New York Heart Association class I/II at the most recent evaluation. It also showed that the risk of embolic stroke, HCM-related death, or all-cause mortality did not differ in patients with paroxysmal and those with permanent AF. Therefore, in many patients with HCM, the transition from unpredictable recurrences of AF to permanent AF with adequate heart rate control appears to be well tolerated and may improve quality of life by freeing the patient from the anxiety of potential recurrences of arrhythmic events and repeated hospitalizations.
Thromboembolism occurred significantly less frequently in patients taking anticoagulant prophylaxis. 7 Left atrial size, number of AF episodes, and AF category (paroxysmal or permanent) were not reliable markers of the risk of stroke. Furthermore, of the 18 study patients with AF (6%) who had an embolic stroke, 5 experienced this event after a single episode of AF. As in previous HCM studies, the CHA 2 DS 2 -VASC score did not predict the stroke risk. Therefore, because of the potentially devastating effects of thromboembolic events, anticoagulation should be taken into consideration in every patient with HCM and AF, independently of left atrial size and number and duration of AF episodes.
Catheter ablation was performed in a subgroup of ≈50 patients (15%) with paroxysmal AF in whom quality of life was severely limited by the AF recurrences. However, freedom from symptomatic recurrence of AF after the initial ablation procedure was only ≈40% at 1 year and 30% at 3 years. These results are consistent with previous studies in HCM. 11, 12 The limited efficacy of catheter ablation can be explained by the complex pathophysiology of HCM, a disease in which diastolic dysfunction and LV outflow obstruction with associated mitral valve regurgitation may lead to high LV filling pressures, progressive left atrial dilatation, and important heart failure, with AF as the result of this cascade of events.
Biatrial Cox-Maze procedures (Cox-Maze III or IV), using both bipolar radiofrequency and cryoablation, were performed in ≈70% of the 100 study patients with LV outflow obstruction and a history of AF who underwent septal myectomy. 7 Because the Cox-Maze procedure is not routinely performed in patients with HCM at the time of septal myectomy and because available data on this procedure are limited to small numbers of patients with HCM, the results are of interest. Freedom from symptomatic recurrence of AF after the Maze was 75% at 1 year and 70% at 3 years. Therefore, this procedure proved to be substantially more effective than catheter ablation of AF. However, it may be difficult to discriminate the favorable effects of the Cox-Maze procedure on AF recurrences from the effects resulting from septal myectomy with abolition of the LV outflow gradient, decrease in mitral valve regurgitation, and possible reduction in left atrial size. In addition, the biatrial CoxMaze III or IV is technically complex, requires a high level of expertise, and may prolong cardiopulmonary bypass time. Therefore, clarification of the role of the Cox-Maze procedure in surgical septal myectomy needs additional investigation.
In conclusion, the study by Rowin et al sheds novel and more favorable light on AF and its impact on the clinical course of HCM. In contrast to previous and older literature, AF does not appear to be a primary cause of HCM-related death or disease progression and is associated with a low mortality. Substantial advances in the overall treatment of HCM during the last 2 decades have undoubtedly contributed to the improved outcome and quality of life of patients with HCM and AF.
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